Terlipressin for Type 1 Hepatorenal Syndrome
Dig Dis Sci
.
2020 Aug;65(8):2454-2455.
doi: 10.1007/s10620-020-06370-8.
Epub 2020 Jun 8.
Authors
R Terbah
1
,
P Gow
1
2
,
M Sinclair
1
2
,
A Testro
3
4
Affiliations
1
Department of Gastroenterology and Liver Transplant Unit, Austin Health, Melbourne, VIC, Australia.
2
The University of Melbourne, Parkville, Melbourne, VIC, Australia.
3
Department of Gastroenterology and Liver Transplant Unit, Austin Health, Melbourne, VIC, Australia. adam.testro@austin.org.au.
4
The University of Melbourne, Parkville, Melbourne, VIC, Australia. adam.testro@austin.org.au.
PMID:
32514642
DOI:
10.1007/s10620-020-06370-8
No abstract available
Publication types
Letter
Comment
MeSH terms
Hepatorenal Syndrome* / drug therapy
Humans
Terlipressin*
Vasoconstrictor Agents / adverse effects
Substances
Vasoconstrictor Agents
Terlipressin